文献速递肺栓塞与肺血管病

肺动脉高压治疗与生存的时间趋势:COMPERA注册研究

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
PubMed 文献 · Eur Respir J · 2022-06-02

该研究分析COMPERA欧洲肺动脉高压注册研究中2010至2019年新诊断PAH患者2531例,评估早期联合治疗使用趋势及生存变化。早期联合治疗比例从2010年的10.0%升至2019年的25.0%,诊断后1年联合治疗比例从27.7%升至46.3%;1年生存率无变化,3年生存率略有改善但无统计学意义。

要点

  • 新诊断PAH早期联合治疗比例从2010年10.0%升至2019年25.0%。
  • 诊断后1年联合治疗比例从27.7%升至46.3%,但多数患者仍接受单药治疗。
  • 2010-2014与2015-2019两期1年生存率相似,3年生存率略有改善但无统计学意义。

核心结论

  • 2010至2019年间联合治疗使用增加,但多数患者仍接受单药治疗。
  • 诊断后1年生存率未随时间变化。
  • 3年生存率略有改善但无统计学意义,需未来研究确认。

研究设计与样本

  • 基于COMPERA欧洲肺动脉高压注册研究的回顾性分析。
  • 纳入2010至2019年新诊断PAH患者共2531例。
  • 生存分析采用年度化数据及2010-2014与2015-2019两期累积数据比较。

主要发现

  • 早期联合治疗(诊断后3个月内)比例从2010年诊断患者的10.0%升至2019年诊断患者的25.0%。
  • 诊断后1年联合治疗比例从27.7%升至46.3%。
  • 2010-2014与2015-2019两期1年生存率分别为89.0%(95%CI 87.2-90.9%)和90.8%(95%CI 89.3-92.4%)。
  • 两期3年生存率分别为67.8%(95%CI 65.0-70.8%)和70.5%(95%CI 67.8-73.4%),差异无统计学意义。

临床怎么用

  • 临床实践中应关注PAH联合治疗的使用,尽管趋势增加但多数患者仍为单药治疗。
  • 1年生存率未随联合治疗增加而改善,提示需进一步评估治疗策略对长期生存的影响。

局限性

  • 3年生存率改善无统计学意义,需未来研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2015, the European pulmonary hypertension guidelines recommend the use of combination therapy in most patients with pulmonary arterial hypertension (PAH). However, it is unclear to what extent this treatment strategy is adopted in clinical practice and if it is associated with improved long-term survival. METHODS: We analysed data from COMPERA, a large European pulmonary hypertension registry, to assess temporal trends in the use of combination therapy and survival of patients with newly diagnosed PAH between 2010 and 2019. For survival analyses, we looked at annualised data and at cumulated data comparing the periods 2010-2014 and 2015-2019. RESULTS: A total of 2531 patients were included. The use of early combination therapy (within 3 months after diagnosis) increased from 10.0% in patients diagnosed with PAH in 2010 to 25.0% in patients diagnosed with PAH in 2019. The proportion of patients receiving combination therapy 1 year after diagnosis increased from 27.7% to 46.3%. When comparing the 2010-2014 and 2015-2019 periods, 1-year survival estimates were similar (89.0% (95% CI 87.2-90.9%) and 90.8% (95% CI 89.3-92.4%), respectively), whereas there was a slight but nonsignificant improvement in 3-year survival estimates (67.8% (95% CI 65.0-70.8%) and 70.5% (95% CI 67.8-73.4%), respectively). CONCLUSIONS: The use of combination therapy increased from 2010 to 2019, but most patients still received monotherapy. Survival rates at 1 year after diagnosis did not change over time. Future studies need to determine if the observed trend suggesting improved 3-year survival rates can be confirmed.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Hoeper MM, Pausch C, Grünig E, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022. PMID: 34675047. doi:10.1183/13993003.02024-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。